- Home
- PSTL vs CCCC Comparison
PSTL vs CCCC Comparison
Compare PSTL & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTL
- CCCC
- Stock Information
- Founded
- PSTL 2018
- CCCC 2015
- Country
- PSTL United States
- CCCC United States
- Employees
- PSTL N/A
- CCCC N/A
- Industry
- PSTL Real Estate Investment Trusts
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- PSTL Real Estate
- CCCC Health Care
- Exchange
- PSTL Nasdaq
- CCCC Nasdaq
- Market Cap
- PSTL 329.8M
- CCCC 175.1M
- IPO Year
- PSTL 2019
- CCCC 2020
- Fundamental
- Price
- PSTL $15.76
- CCCC $3.41
- Analyst Decision
- PSTL Strong Buy
- CCCC Strong Buy
- Analyst Count
- PSTL 1
- CCCC 3
- Target Price
- PSTL $17.75
- CCCC $8.67
- AVG Volume (30 Days)
- PSTL 149.1K
- CCCC 1.3M
- Earning Date
- PSTL 11-03-2025
- CCCC 10-30-2025
- Dividend Yield
- PSTL 6.16%
- CCCC N/A
- EPS Growth
- PSTL 344.13
- CCCC N/A
- EPS
- PSTL 0.39
- CCCC N/A
- Revenue
- PSTL $86,535,000.00
- CCCC $34,240,000.00
- Revenue This Year
- PSTL $22.00
- CCCC N/A
- Revenue Next Year
- PSTL $9.76
- CCCC N/A
- P/E Ratio
- PSTL $40.71
- CCCC N/A
- Revenue Growth
- PSTL 26.43
- CCCC 16.55
- 52 Week Low
- PSTL $12.26
- CCCC $1.09
- 52 Week High
- PSTL $16.06
- CCCC $7.14
- Technical
- Relative Strength Index (RSI)
- PSTL 59.58
- CCCC 70.84
- Support Level
- PSTL $15.76
- CCCC $2.58
- Resistance Level
- PSTL $16.06
- CCCC $3.65
- Average True Range (ATR)
- PSTL 0.20
- CCCC 0.23
- MACD
- PSTL -0.03
- CCCC 0.06
- Stochastic Oscillator
- PSTL 47.41
- CCCC 81.82
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.